tumor microenvironment News
-
Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in Glioblastoma
Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announces that preliminary findings from its Phase 1/2a of Temferon™ in the treatment of patients with glioblastoma multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM) provide initial evidence of ...
-
Single Cell Sequencing: Transform Your Immunology and Cancer Research from Bulk to Single Cell Analysis
Single cell sequencing has transformed our ability to discern the cellular and molecular makeup of human immune systems and tissues in a unique manner with a level of precision that other “omic” technologies are unable to provide. Coupled with rigorous analysis, this technology is able to identify rare cell populations/subtypes and provide novel insights about pathways and thus ...
-
Actym Therapeutics Will Present Data at the 2019 Society for the Immunotherapy of Cancer (SITC) Annual Meeting
Actym Therapeutics, a privately held biotechnology company focused on therapeutic targeting of intractable immune pathways in the tumor microenvironment, announced today that it will be presenting data at the SITC Annual Meeting in National Harbor, Maryland on November 9, 2019. The presentation is entitled “STACT: A Novel Therapeutic Platform that Delivers Immunomodulatory Payloads to ...
-
PsiOxus and bluebird bio Present Novel Data Combining PsiOxus T-SIGn Platform with CAR-T Therapy to Clear Primary Tumors and Metastases
Single IV cycle of PsiOxus’ T-SIGn vector enabled an otherwise non-effective dose of CAR-T cell therapy to clear primary and metastatic tumors in vivo Reprogramming of the tumor microenvironment using T-SIGn vectors could enable a variety of CAR-T therapies to overcome limitations in solid tumors Data is currently being presented at the AACR Virtual Annual Meeting 2021 OXFORD, UK ...
-
T3 Pharma wins prestigious Falling Walls Venture Award for its bacterial cancer therapy
T3 Pharmaceuticals (“T3 Pharma”), a biotech company with a focus on immuno-oncology, today announced it has been named “2018 Science Start-Up of the Year” by Falling Walls Venture. The award honors emerging scientist-entrepreneurs for their breakthrough business models. The Falling Walls Conference in Berlin, Germany, annually invites the world’s leading scientists ...
-
Tactiva Therapeutics Announces License to Oncolytic Vaccinia Virus Armed With CXCR4 Antagonist for Treatment of Ovarian Cancer
Buffalo, NY based Tactiva Therapeutics, Inc. announced they’ve licensed new intellectual property from the Roswell Park Cancer Institute Corporation that covers the use of the Oncolytic Vaccinia Virus (OVV) armed with a CXCR4 antibody. Pre-clinical results recently published in the Journal of Immunology (August 2018) demonstrate a potent therapeutic response with an ability to control ...
-
PsiOxus Therapeutics Announces Clinical Trial with Third Cancer Gene Therapy Treatment and Appointment of New Chief Medical Officer.
March 05, 2020 – OXFORD, UK – PsiOxus® Therapeutics, Ltd. (PsiOxus), the gene therapy for cancer company, today announced that it has started a clinical trial with NG-641, a four transgene tumor-microenvironment modifying cancer gene therapy. This is the first time that a tumor- specific virus containing four different therapeutic transgenes has been administered to cancer ...
-
Obsidian Therapeutics Announces Bristol Myers Squibb Opt-In of cytoDRiVE™ Cell Therapy Candidate
Obsidian Therapeutics, Inc., a biotechnology company pioneering controllable cell and gene therapies, today announced that Bristol Myers Squibb (NYSE:BMY) has exercised its option to an exclusive worldwide license to a cell therapy candidate based on Obsidian’s cytoDRiVE™ technology for the controlled expression of the immunomodulatory factor CD40L. This announcement marks the first ...
-
Senti Bio to Present Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at AACR Annual Meeting
Senti Bio, a leading gene circuit company, today announced the acceptance of an abstract for presentation at the American Association for Cancer Research (AACR) annual meeting in New Orleans taking place April 8–13, 2022. The abstract, titled “Driving anti-tumor activity in solid tumors with controlled arming of allogeneic CAR-NK cells,” details the Company’s efforts to ...
-
Second Genome Presents New Preclinical Data at AACR 2022 Demonstrating that SG-3-06686, a CXCR3 Chemokine Receptor Modulator, Induces Migration of Immune Effector Cells, Inhibits Tumor Growth as Monotherapy and Boosts Anti-Programmed Death Protein-1 (PD-1
Lead oncology program candidate SG-3-06686 shows potential to become first in class CXCR3 immune activator Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, presented data demonstrating the Company’s CXCR3 chemokine receptor modulator, SG-3-06686 (referred to as SG-3-00802DC in the AACR ...
-
Xilis Participates in €325MM Oncode-PACT Consortium to Accelerate the Development of Cancer Drugs
Xilis, Inc., a pioneering company developing its MicroOrganoSphere™ (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, announced today that it is participating in the recently announced public-private Oncode-PACT. Led by the Netherlands-based Oncode Institute, the consortium will be supported by the National Growth Fund, an ...
By XILIS, Inc.
-
Tactiva Therapeutics Co-Founder Kunle Odunsi Elected to National Academy of Medicine
BUFFALO, N.Y., October 16, 2018 — Tactiva Therapeutics, a development stage company targeting a broad range of cancers, announced today that its co-founder Kunle Odunsi, M.D., Ph.D., FRCOG, FACOG, is among the 75 newly elected regular members of the National Academy of Medicine (NAM). Membership of the NAM is considered one of the highest honors in the field of health and medicine and ...
-
Immune-Onc Therapeutics Announces the Selection of Clinical Development Candidate IO-106, a First-in-Class Myeloid and Stromal Checkpoint Inhibitor Targeting LAIR1
IO-106 is the third development candidate arising from Immune-Onc’s pioneering pipeline of myeloid checkpoint inhibitors, a new class of immunotherapy that aims to overcome immune resistance in cancer The Company will present a scientific poster at the Society for Immunotherapy of Cancer (SITC) Tumor Immune Microenvironment: A Holistic Approach Workshop Immune-Onc ...
-
ORYX Announces Positive Phase I/IIa Data for Oncolytic Virus ParvOryx Demonstrating Safety, Anti-tumor Effects, Partial Responses and Prolonged Overall Survival in Metastatic, Inoperable Pancreatic Cancer
ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, today published positive clinical trial results from a dose-escalating Phase I/IIa trial with oncolytic virus ParvOryx in metastatic, inoperable pancreatic cancer. ParvOryx, a wild type rat oncolytic parvovirus (H-1PV), was evaluated in an open label study in seven patients with metastatic, inoperable ...
-
Antengene Announces IND Approval for the Phase I STAMINA-001 Study to Evaluate ATG-037 (CD73 Inhibitor) for the Treatment of Locally Advanced or Metastatic Solid Tumors in China
ATG-037, an inhouse asset developed by Antengene and with global rights, has been approved to enter clinical studies in Australia and China, thus becoming the first oral small molecule CD73 inhibitor entering the clinical-stage in China and the wider Asia Pacific region. ATG-037 IND in Australia has been started enrolling in that phase I study. -The STAMINA-001 study will evaluate ATG-037 as a ...
-
Xilis Presents Data at ESMO 2021 Demonstrating Capabilities of MicroOrganoSphere Technology for Cancer Drug Screening
Data suggests MOS platform recapitulates primary tumor tissue heterogeneity, including genomic and transcriptomic features, and microenvironment, comprising immune and stromal components MOS can be used in the evaluation of cancer drug response for chemotherapies and immunotherapies in the research setting Xilis, Inc., a pioneering company developing its MicroOrganoSphere (MOS) technology ...
By XILIS, Inc.
-
CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that the first patient has been dosed in a Phase 1 dose-escalation study of CX-904 (NCT05387265). CX-904 is a conditionally activated T-cell-engaging bispecific (TCB) designed to target the epidermal growth factor receptor (EGFR) on cancer cells and the CD3 receptor on ...
-
Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma Multiforme
Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, will present clinical data from its Phase 1/2a dose-escalation study of its clinical-stage candidate Temferon™ in patients with glioblastoma multiforme (GBM) who have an unmthylated MGMT gene promotor (uMGMT-GBM) at the ...
-
Actym Therapeutics Raises $34 Million Series A ?
Actym Therapeutics, a privately-held immuno-oncology company, announced today the completion of a $34 million series A financing led by Boehringer Ingelheim Venture Fund (BIVF) and Panacea Venture, with participation from Illumina Ventures, Korea Investment Partners (KIP), and JLo Ventures. The company will use the proceeds to advance development of immunotherapies from its microbial-based STACT ...
-
Actym Therapeutics, Inc. today announced the appointment of Chan Whiting, Ph.D. as Chief Development Officer
Actym Therapeutics hires Dr. Chan Whiting as Chief Development Officer. Chan brings over 20 years of drug development experience within the biotechnology industry. As CDO, Chan will play a key leadership role in advancing Actym's pipeline of first-in-class, systemically administered therapeutics that re-program the immunosuppressive microenvironment in solid tumors. "Chan has significant ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you